4 completed, 1 withdrawn. 3 Phase 1, 2 Phase 2.
By phase and status
Follow BMS-986141: new trials by email Literature Review of BMS-986141 trials Research Report on BMS-986141
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
Ticagrelor, BMS-986141, Aspirin - Coronary Artery Disease, Healthy Participants | Phase 2 | Completed | Bristol-Myers Squibb | 58 | 2022-03-25 | 2023-12-05 |
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
BMS-986141 - Hepatic Impairment | Phase 1 | Withdrawn | Bristol-Myers Squibb | | 2017-01-11 | 2017-02-06 |
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
BMS-986141, Dilitazem - Ischemic Stroke | Phase 1 | Completed | Bristol-Myers Squibb | 16 | 2016-09-01 | 2016-12-20 |
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
BMS-986141, Aspirin, Placebo - Thrombosis | Phase 2 | Completed | Bristol-Myers Squibb | 16 | 2016-04-25 | 2018-12-14 |
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
BMS-986141, Placebo, Aspirin - Thrombosis | Phase 1 | Completed | Bristol-Myers Squibb | 148 | 2014-09-01 | 2017-03-31 |
Conditions studied
Thrombosis (3) · Coronary Artery Disease (1) · Ischemic Stroke (1)
Sponsors
Bristol-Myers Squibb (5)
Countries
United States (4) · Japan (1) · United Kingdom (1)
Results publications
PMID 37394920, PMID 38357820